Involvement of Angiotensin II-Dependent Vascular Endothelial Growth Factor Gene Expression via NADPH Oxidase in the Retina in a Type 2 Diabetic Rat Model

REFERENCES

• Klein R, Klein B E, Moss S E. Epidemiology of proliferative diabetic retinopathy. Diab Care 1992; 15: 1875–1891
   PubMed Web of Science ®Google Scholar
• VanNewkirk M R, Weih L, McCarty C A, Taylor H R. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology 2001; 108: 960–967
   PubMed Web of Science ®Google Scholar
• Kempen J H, O'Colmain B J, Leske M C, Haffner S M, Klein R, Moss S E, Taylor H R, Hamman R F. Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552–563
   PubMed Web of Science ®Google Scholar
• Frank R N. Diabetic retinopathy. N Engl J Med 2004; 350: 48–58
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317: 703–713
   PubMed Web of Science ®Google Scholar
• Wan Nazaimoon W, Letchuman R, Noraini N, Ropilah A, Zainal M, Ismail I, Wan Mohamad W, Faridah I, Singaraveloo M, Sheriff I, Khalid B. Systolic hypertension and duration of diabetes mellitus are important determinants of retinopathy and microalbuminuria in young diabetics. Diabetes Res Clin Pract 1999; 46: 213–221
   PubMed Web of Science ®Google Scholar
• Kohler K, Wheeler-Schilling T, Jurklies B, Guenther E, Zrenner E. Angiotensin II in the rabbit retina. Vis Neurosci 1997; 14: 63–71
   PubMed Web of Science ®Google Scholar
• Danser A H, Derkx F H, Admiraal P J, Deinum J, de Jong P T, Schalekamp M A. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008–1018
   PubMed Web of Science ®Google Scholar
• Moravski C J, Kelly D J, Cooper M E, Gilbert R E, Bertram J F, Shahinfar S, Skinner S L, Wilkinson-Berka J L. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099–1104
   PubMed Web of Science ®Google Scholar
• Moravski C J, Skinner S L, Stubbs A J, Sarlos S, Kelly D J, Cooper M E, Gilbert R E, Wilkinson-Berka J L. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: Transgenic and interventional studies. Am J Pathol 2003; 162: 151–160
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Sjolie A K, Stephenson J M, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller J H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31
   PubMed Web of Science ®Google Scholar
• Caldwell R B, Bartoli M, Behzadian M A, El-Remessy A E, Al-Shabrawey M, Platt D H, Liou G I, Caldwell R W. Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets 2005; 6: 511–524
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Nawata H. NAD(P)H oxidase activation: A potential target mechanism for diabetic vascular complications, progressive β -cell dysfunction, and metabolic syndrome. Curr Drug Targets 2005; 6: 495–501
   PubMed Web of Science ®Google Scholar
• Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin J L, Hofmann S M, Vlassara H, Shi Y. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003; 108: 472–478
   PubMed Web of Science ®Google Scholar
• Al-Shabrawey M, Bartoli M, El-Remessy A B, Platt D H, Matragoon S, Behzadian M A, Caldwell R W, Caldwell R B. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 2005; 167: 599–607
   PubMed Web of Science ®Google Scholar
• Shinohara M, Masuyama T, Shoda T, Takahashi T, Katsuda Y, Komeda K, Kuroki M, Kakehashi A, Kanazawa Y. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000; 1: 89–100
   PubMedGoogle Scholar
• Yamada H, Yamada E, Higuchi A, Matsumura M. Retinal neovascularization without ischemia in the spontaneously diabetic Torii rat. Diabetologia 2005; 48: 1663–1668
   PubMed Web of Science ®Google Scholar
• Tanaka H, Takai S, Jin D, Furubayashi K, Inoue N, Kajimoto Y, Miyatake S, Kuroiwa T, Miyazaki M. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 2007; 30: 469–475
   PubMed Web of Science ®Google Scholar
• Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, Miyazaki M. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593–600
   PubMed Web of Science ®Google Scholar
• Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens 2003; 21: 361–369
   PubMed Web of Science ®Google Scholar
• Ishizaki E, Takai S, Ueki M, Maeno T, Maruichi M, Sugiyama T, Oku H, Ikeda T, Miyazaki M. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006; 141: 129–134
   PubMed Web of Science ®Google Scholar
• Aiello L P, Avery R L, Arrigg P G, Keyt B A, Jampel H D, Shah S T, Pasquale L R, Thieme H, Iwamoto M A, Park J E, Nguyen H V, Aiello L M, Ferrara N, King G L. Vascular endothelial growth factor in ocular fluid of 445 patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487
   PubMed Web of Science ®Google Scholar
• Amin R H, Frank R N, Kennedy A, Eliott D, Puklin J E, Abrams G W. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 36–47
   PubMed Web of Science ®Google Scholar
• Adamis A P, Miller J W, Bernal M T, D'Amico D J, Folkman J, Yeo T K, Yeo K T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445–450
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56: 794–814
   PubMed Web of Science ®Google Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527–543
   PubMed Web of Science ®Google Scholar
• Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, Honda Y. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000; 41: 1192–1199
   PubMed Web of Science ®Google Scholar
• Ushio-Fukai M, Alexander R W. Reactive oxygen species as mediators of angiogenesis signaling: Role of NAD(P)H oxidase. Mol Cell Biochem 2004; 264: 85–97
   PubMed Web of Science ®Google Scholar
• Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005; 23: 97–104
   PubMed Web of Science ®Google Scholar
• Ellis E A, Grant M B, Murray F T, Wachowski M B, Guberski D L, Kubilis P S, Lutty G A. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Rad Biol Med 1998; 24: 111–120
   PubMed Web of Science ®Google Scholar
• Grassi G. Diabetic retinopathy. Minerva Med 2003; 94: 419–435
   PubMedGoogle Scholar
• Schalkwijk C G, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers H G, Schlingemann R O, Tarnow L, Parving H H, Stehouwer C D, van Hinsbergh V W. Amadori albumin in type 1 diabetic patients: Correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999; 48: 2446–2453
   PubMed Web of Science ®Google Scholar
• Stitt A W, Li Y M, Gardiner T A, Bucala R, Archer D B, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150: 523–531
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213–20220
   PubMed Web of Science ®Google Scholar
• Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928–1930
   PubMed Web of Science ®Google Scholar
• Li L, Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006; 55: 1516–1523
   PubMed Web of Science ®Google Scholar
• Mamputu J C, Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diabetes Compl 2002; 16: 284–293
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Okuno T, Fukuhara M, Oku H, Ikeda T, Obayashi H, Ohta M, Fukui M, Hasegawa G, Nakamura N. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 2007; 85: 406–412
   PubMed Web of Science ®Google Scholar
• Polonsky K S, Sturis J, Bell G I. Non-insulin-dependent diabetes mellitus A genetically programmed failure of the β cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777–783
   PubMed Web of Science ®Google Scholar
• Sjølie A K, Porta M, Parving H H, Bilous R, Klein R. The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: Baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005; 6: 25–32
   PubMed Web of Science ®Google Scholar